88 related articles for article (PubMed ID: 32894980)
1. Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer.
Gagno S; Bartoletti M; Romualdi C; Poletto E; Scalone S; Sorio R; Zanchetta M; De Mattia E; Roncato R; Cecchin E; Giorda G; Toffoli G
Pharmacogenomics; 2020 Sep; 21(14):995-1010. PubMed ID: 32894980
[No Abstract] [Full Text] [Related]
2. A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
Gagno S; Poletto E; Bartoletti M; Quartuccio L; Romualdi C; Garziera M; Scalone S; Sorio R; Dreussi E; Zanusso C; De Mattia E; Roncato R; Cecchin E; Giorda G; De Vita S; Dal Bo M; Puglisi F; Toffoli G
Gynecol Oncol; 2020 Jan; 156(1):233-242. PubMed ID: 31711657
[TBL] [Abstract][Full Text] [Related]
3. Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.
Despierre E; Moisse M; Yesilyurt B; Sehouli J; Braicu I; Mahner S; Castillo-Tong DC; Zeillinger R; Lambrechts S; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I
Gynecol Oncol; 2014 Dec; 135(3):415-22. PubMed ID: 25281495
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy.
Miao Y; Li S; Yan Q; Li B; Feng Y
Oncol Res Treat; 2016; 39(11):712-719. PubMed ID: 27855385
[TBL] [Abstract][Full Text] [Related]
5. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW
Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659
[TBL] [Abstract][Full Text] [Related]
6. The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms.
Heubner M; Wimberger P; Riemann K; Kasimir-Bauer S; Otterbach F; Kimmig R; Siffert W
Oncol Res; 2010; 18(7):343-7. PubMed ID: 20377136
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
Trillsch F; Mahner S; Hilpert F; Davies L; García-Martínez E; Kristensen G; Savarese A; Vuylsteke P; Los M; Zagouri F; Gladieff L; Sehouli J; Khoon Lee C; Gebski V; Pujade-Lauraine E
Ann Oncol; 2016 Sep; 27(9):1733-9. PubMed ID: 27287207
[TBL] [Abstract][Full Text] [Related]
8. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
9. Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer.
Tan J; Song C; Wang D; Hu Y; Liu D; Ma D; Gao Q
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33891016
[TBL] [Abstract][Full Text] [Related]
10. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
11. Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy.
Luo S; Zhang Y; Yang Y; Zhu S; Liu W; Zhu J; Liang X; Jiang Z; Sun S; Hou X; Xiao Y; Li X
Gynecol Oncol; 2020 Jul; 158(1):66-76. PubMed ID: 32402633
[TBL] [Abstract][Full Text] [Related]
12. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A
Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
14. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
[No Abstract] [Full Text] [Related]
15. Location of Mutation in
Labidi-Galy SI; Olivier T; Rodrigues M; Ferraioli D; Derbel O; Bodmer A; Petignat P; Rak B; Chopin N; Tredan O; Heudel PE; Stuckelberger S; Meeus P; Meraldi P; Viassolo V; Ayme A; Chappuis PO; Stern MH; Houdayer C; Stoppa-Lyonnet D; Buisson A; Golmard L; Bonadona V; Ray-Coquard I
Clin Cancer Res; 2018 Jan; 24(2):326-333. PubMed ID: 29084914
[No Abstract] [Full Text] [Related]
16. Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer.
Kobayashi-Kato M; Yunokawa M; Bun S; Miyasaka N; Kato T; Tamura K
Cancer Chemother Pharmacol; 2019 Jul; 84(1):33-39. PubMed ID: 30982097
[TBL] [Abstract][Full Text] [Related]
17. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
[TBL] [Abstract][Full Text] [Related]
18. Clinical response to antiestrogen therapy in platinum-resistant ovarian cancer patients and the role of tumor estrogen receptor expression status.
Stasenko M; Plegue M; Sciallis AP; McLean K
Int J Gynecol Cancer; 2015 Feb; 25(2):222-8. PubMed ID: 25500503
[TBL] [Abstract][Full Text] [Related]
19. Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer.
Nicoletto MO; Bertorelle R; Borgato L; De Salvo GL; Artioli G; Lombardi G; Zustovich F; Marcato R; Parenti A; Montagna M; Donach ME
Int J Gynecol Cancer; 2009 Aug; 19(6):1022-8. PubMed ID: 19820363
[TBL] [Abstract][Full Text] [Related]
20. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
